Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 4/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 3/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313506 | 0.81 | CES2 (0.36) | CES2CES1GPR84 | |
| SCHEMBL29487566 | 0.81 | CES2 (0.36) | CES2CES1GPR84 | |
| SCHEMBL2842027 | 0.79 | AKR1B1 (0.35) | KDM1AKCNH2KDM1B | |
| SCHEMBL29544666 | 0.79 | KDM1A (0.41) | CES2CES1KDM1AKCNH2KDM1B | |
| SCHEMBL577838 | 0.79 | KDM1A (0.41) | CES2CES1KDM1AKCNH2KDM1B | |
| SCHEMBL13738335 | 0.78 | KDM1A (0.34) | CES2CES1KDM1AKCNH2KDM1B | |
| SCHEMBL1770614 | 0.77 | KDM1A (0.35) | KDM1AKCNH2KDM1B | |
| SCHEMBL29365299 | 0.77 | KDM1A (0.35) | KDM1AKCNH2KDM1B | |
| SCHEMBL11131552 | 0.72 | TP53 (0.32) | CES2CES1 | |
| SCHEMBL112218 | 0.72 | HDAC4 (0.36) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118638155-A | Benzoxepin compound, preparation method and application thereof | 黑龙江大学 | 2024-09-13 | — | — | CN | claimed |
| US-10598641-B2 | Methods for determining instrument linearity and quantification | THERMO FINNIGAN LLC (US) | 2020-03-24 | — | — | US | claimed |
| US-20190195843-A1 | METHODS FOR DETERMINING INSTRUMENT LINEARITY AND QUANTIFICATION | THERMO FINNIGAN LLC | 2019-06-27 | — | — | US | claimed |
| CN-118638155-A | Benzoxepin compound, preparation method and application thereof | 黑龙江大学 | 2024-09-13 | — | — | CN | disclosed |
| CN-111051284-B | Compound and organic light emitting device including the same | 株式会社LG化学 | 2023-04-18 | — | — | CN | disclosed |
| EP-3452471-B1 | ORGANIC MOLECULES, ESPECIALLY FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-12-08 | — | — | EP | disclosed |
| CN-109071501-B | Organic molecules, in particular for organic opto-electronic devices | 辛诺拉有限公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-111051284-A | Compound and organic light emitting device including the same | 株式会社LG化学 | 2020-04-21 | — | — | CN | disclosed |
| WO-2019190248-A9 | COMPOUND AND ORGANIC LIGHT EMITTING DIODE COMPRISING SAME | 주식회사 엘지화학 | 2020-04-02 | — | — | WO | disclosed |
| US-10598641-B2 | Methods for determining instrument linearity and quantification | THERMO FINNIGAN LLC (US) | 2020-03-24 | — | — | US | disclosed |
| US-10598641-B2 | Methods for determining instrument linearity and quantification | THERMO FINNIGAN LLC (US) | 2020-03-24 | — | — | US | disclosed |
| EP-1498406-A1 | Novel hydronaphthalene compounds, prepared by a rhodium catalysed ring opening reaction in the presence of phosphine ligand | AstraZeneca AB (SE) | 2005-01-19 | — | — | EP | disclosed |
| EP-1228024-B1 | NOVEL HYDRONAPHTHALENE COMPOUNDS, PREPARED BY A RHODIUM CATALYZED RING OPENING REACTION IN THE PRESENCE OF PHOSPHINE LIGAND | ASTRAZENECA AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-6784210-B2 | DECYCLIZATION OF OXABENZONORBORNADIENES OR AZABICYCLIC COMPOUNDS IN THE PRESENCE OF CATALYSTS TO FORM NAPHTHALENES, SUCH AS 2-METHOXY-1,2-DIHYDRONAPHTHALEN-1-OL, USED AS ANALGESICS, ANTICARCINOGENS OR VIRICIDES; CATALYSIS | ASTRAZENECA AB (SE) | 2004-08-31 | — | — | US | disclosed |
| US-20030144275-A1 | Decyclization of oxabenzonorbornadienes or azabicyclic compounds in the presence of catalysts to form naphthalenes, such as 2-methoxy-1,2-dihydronaphthalen-1-ol, used as analgesics, anticarcinogens or viricides; catalysis | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
| US-6525068-B1 | Such as 2-pyrrolidin-1-yl-1,2-dihydro-naphthalen-1-ol; reac-tion of oxabenzonorbornadienes with nucleophiles; pain, parkinson's disease, cancer, aids | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| EP-1228024-A1 | NOVEL HYDRONAPHTALENE COMPOUNDS, PREPARED BY A RHODIUM CATALYZED RING OPENING REACTION IN THE PRESENCE OF PHOSPHINE LIGAND | AstraZeneca AB (SE) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001030734-A1 | NOVEL HYDRONAPHTALENE COMPOUNDS, PREPARED BY A RHODIUM CATALYZED RING OPENING REACTION IN THE PRESENCE OF PHOSPHINE LIGAND | ASTRAZENECA AB (SE) | 2001-05-03 | — | — | WO | disclosed |
| EP-0648724-B1 | Process for the preparation of 1-Bromo-3,5-difluorobenzene | HOECHST AG (DE) | 1997-07-30 | — | — | EP | disclosed |
| EP-0648724-A1 | Process for the preparation of 1-Bromo-3,5-difluorobenzene | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144275-A1 | Decyclization of oxabenzonorbornadienes or azabicyclic compounds in the presence of catalysts to form naphthalenes, such as 2-methoxy-1,2-dihydronaphthalen-1-ol, used as analgesics, anticarcinogens or viricides; catalysis | DDT, HPD, DHODH | CES2 676/4885CES1 868/4885BCHE 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.